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Abstract
Introduction The absence of mutation or promoter
hypermethylation in the BRCA2 gene in the majority of breast
cancer cases has indicated alternative ways of its involvement,
deregulated expression being one possibility. We show how a
polymorphism in the 5' untranslated region (UTR) of BRCA2
can serve as one such factor. Based on the hypothesis that
variants of genes involved in the same pathway can influence the
risk provided for breast cancer, the status of p53 codon 72
polymorphism was also investigated and a possible interaction
between the polymorphisms was examined.
Methods The luciferase reporter assay followed by RNA
secondary structure analysis was used for the functional
characterization of -26 5' UTR G>A polymorphism in BRCA2.
The genotype and the allele frequency for the polymorphisms
were determined and relative risk adjusted for age was
calculated in a case-control study of 576 individuals (243
patients and 333 controls) from north India.
Results -26 G>A polymorphism in the 5' UTR of BRCA2 was
found to be functional whereby the A allele increased the
reporter gene expression by twice that of the G allele in MCF-7
(P  = 0.003) and HeLa (P  = 0.013) cells. RNA secondary
structure analysis by two different programs predicted the A
allele to alter the stability of a loop in the vicinity of the translation
start site. Its direct implication in breast cancer became evident
by a case-control study in which the heterozygous genotype
was found to be protective in nature (Pheterozygote advantage model =
0.0005, odds ratio [OR] = 0.5, 95% confidence interval [CI] =
0.4 to 0.8), which was further supported by trends observed in
a genomic instability study. The p53 codon 72 Arg homozygous
genotype was found to be over-represented in patients (P =
0.0005, OR = 2.3, 95% CI = 1.4 to 3.6). The interaction study
indicated an increased protection under simultaneous presence
of protector genotypes of both the polymorphic loci (P  =
0.0001, OR = 0.2, 95% CI = 0.1 to 0.4).
Conclusion Our study shows that -26 5' UTR polymorphism in
BRCA2  can modulate the fine-tuned regulation of the
multifunctional gene BRCA2  and renders risk or protection
according to the genotype status in the sporadic form of breast
cancer, which is further influenced by the germline genetic
backgrounds of codon 72 polymorphism of p53.
Introduction
BRCA2, since its discovery as a breast cancer susceptibility
gene [1], has been implicated in processes fundamental to all
cells, including proliferation [2], development [3,4], DNA
repair [5,6], transcription [7], and centrosome duplication [8].
Consistent with the tumor suppressor status of the gene,
tumors that develop in carriers of heterozygous BRCA2 muta-
tions are frequently associated with loss of heterozygosity at
the BRCA2 locus [9]. Inherited mutations in the gene continue
to be associated with the familial form of breast, ovarian, and
other types of cancer [10,11], which represent only a small
proportion of the total cases. The role of BRCA2 in the devel-
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opment of the sporadic form of breast cancer remains unde-
fined. Although loss of heterozygosity of the BRCA2 locus has
been detected in more than 50% of sporadic breast tumors
[12], somatic mutations [13-15] or inactivation by methylation
has been either absent or rare [16]. The involvement of altered
expression of BRCA2 in the development of sporadic breast
cancer is a possibility.
BRCA2 gene expression, owing to its functional relevance, is
tightly regulated by several known and unknown factors, which
in turn could be candidates responsible for the deregulated
expression of BRCA2, thus leading to cancer. Its expression
is elevated indirectly in response to the mitogenic activity of
estrogen, which has been associated with progression of the
cell cycle [3]. Cell cycle-dependent expression has been asso-
ciated with binding of the upstream stimulatory factor protein
and EIf-1 transcription factor to the BRCA2 promoter [17].
Wu and colleagues [18] provided evidence for direct induc-
tion of the BRCA2 promoter through binding of nuclear factor-
kappa B. BRCA2 shares a complex regulatory loop with p53
that may be directly associated with the cellular response to
DNA damage. BRCA2 limits the length or severity of the p53-
mediated cell cycle-arrest phenotype by inhibiting transactiva-
tion activity of p53  [4,19,20], and p53  represses  BRCA2
expression in response to genotoxic stress [21].
Thus, polymorphisms in the regulatory region of the BRCA2
gene, which can modulate the fine-tuned regulation of its
expression, are logical candidates to provide risk for breast
cancer. In the present study, we ascertain the functional role
of a common polymorphism -26 G>A (GenBank accession
number AY151039, rs1799943) in the 5' untranslated region
(UTR) of the BRCA2 gene and test its implications in breast
cancer pathogenesis. Furthermore, it has been hypothesized
that breast cancer is a complex disease and that variants in
multiple biologically related genes combine to affect the risk.
In light of the fact that there is a functional interaction between
BRCA2 and p53 in the DNA damage response pathway, the
status of the widely studied p53 codon 72 Arg/Pro polymor-
phism [22-41] and its interaction with -26 BRCA2 polymor-
phism was also evaluated.
Materials and methods
Cloning of BRCA2 promoter + 5' UTR
The minimal promoter of BRCA2 and the 5' UTR with A or G
at the -26 position (HUGO nomenclature) was amplified from
already genotyped healthy control DNA, using the following
primers: forward 5'-GATACTGACGGTTGGGATG-3' and
reverse 5'-ATTTTTACCTACGATATTCCT-3' with long
polymerase chain reaction (PCR) enzyme mix (Fermentas
Canada Inc., Burlington, ON, Canada). The amplified product
was cloned in TOPO cloning vector (Invitrogen Corporation,
Carlsbad, CA, USA). It was then digested with Kpn and XhoI
(Fermentas Canada Inc.) for cloning into pGL3 basic vector
(Promega Corporation, Madison, WI, USA). Sequencing
(Applied Biosystems, Foster City, CA, USA) was performed to
confirm positive clones and the change at -26 5' UTR.
Cell culture
Human breast adenocarcinoma MCF-7 and cervical carci-
noma HeLa cells were propagated in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% bovine calf
serum and maintained at 37°C with 5% CO2 (cell culture rea-
gents were obtained from Life Technologies, Inc., now part of
Invitrogen Corporation).
Transient transfection and luciferase assays
Plasmid DNA was isolated using the plasmid maxi kit (Qiagen
Inc., Valencia, CA, USA) for transient transfection. MCF-7 and
HeLa cells were plated at a density of 1 × 105 cells per well in
six-well plates and grown in DMEM with 10% bovine calf
serum overnight, prior to transfection. All transfections were
carried out using PolyFect (Qiagen Inc.) according to the man-
ufacturer's instructions. A total of 1 μg of BRCA2 promoter
construct and 0.1 μg of pRL-TK Renilla  luciferase vector
(Promega Corporation) with 5 μL of PolyFect were used for
each transfection. The pRL-TK Renilla luciferase activity was
used as a control for transfection efficiency. Each transfection
experiment was performed in duplicate and repeated a mini-
mum of three times. Firefly luciferase and Renilla luciferase
assays were performed using the Dual-Luciferase Reporter
Assay System (Promega Corporation). Approximately 48
hours after transfection, cells were washed twice with 1×
phosphate-buffered saline and harvested with 600 μL of pas-
sive lysis buffer (Promega Corporation). Cell lysates were
cleared by centrifugation, and 5 μL was added to 100 μL of
firefly luciferase substrate, and light units were measured in a
luminometer (TD-20/20, DLReady; Turner Designs, Inc., Sun-
nyvale, CA, USA, and Promega Corporation). Renilla  luci-
ferase activities were measured in the same tube after addition
of 100 μL of Stop and Glo reagent. For adriamycin (ADR)
(Sigma-Aldrich, St. Louis, MO, USA) treatment experiments,
MCF-7 and HeLa cells were transfected, grown for 24 hours,
and exposed to 0, 1, and 2.5 μM ADR for 1 hour in standard
medium. The cells were washed with serum-free medium and
incubated at 37°C in fresh culture medium for another 24
hours before harvesting for luciferase assay.
Cases and controls
A total of 576 peripheral blood samples from north India were
studied for the germline status of polymorphisms in the 5' UTR
of BRCA2 and codon 72 of the p53 gene. This included 243
patients with sporadic breast cancer and 333 unrelated,
healthy female controls with no history of breast cancer. In 145
of the 243 patients, tumors along with corresponding blood
samples and adjacent normal tissues (only in 5 cases in which
blood sample was not available) were also obtained to assess
the somatic status of the mentioned amplified regions and
genomic instability for the informative markers (mentioned
below) established over a period of time in our laboratory in aAvailable online http://breast-cancer-research.com/content/9/5/R71
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pair study. Care was taken that both cases and controls were
ethnically and geographically matched. Prior approval was
given by the Jawaharlal Nehru University ethical committee
and the concerned subjects for sample collection and study.
The tissue samples were frozen immediately after collection
and stored at -80°C until use. DNA was extracted from the
peripheral blood leucocytes and from tissues according to the
standard phenol-chloroform method.
Polymorphism study
PCR was performed under conditions similar to those
described earlier [42] with the following primer sequences
(respective annealing temperatures are mentioned alongside):
-26G>A polymorphism in BRCA2, forward 5'-CTC AGT CAC
ATA ATA AGG AAT-3' and reverse 5'-ACA CTG TGA CGT
ACT GGG TTT T-3' (55°C) and exon 4 codon 72 Arg>Pro
polymorphism, forward 5'-TGC TCT TTT CAC CCA TCT AC-
3' and reverse 5'-ATA CGG CCA GGC ATT GAA GT-3'
(62°C). Thereafter, polymorphisms were detected by
sequencing of their respective PCR products.
Genomic instability analysis
Mutation analysis of exons 5 to 8 of the p53 gene and allelic
imbalance study using three informative markers each in chro-
mosome 16 (D16S3082, D16S423, and D16S413) and
chromosome 17 (D17S379, D17S934, and D17S787) were
carried out according to the procedure mentioned earlier [42]
in 145 of 243 paired samples.
Statistical analysis
First, overall genotype frequencies of breast cancer patients
and control subjects were compared using the 3 × 2 chi-
square test. Once a significant overall difference between
patients and controls subjects was detected (P < 0.05), the
individual genotypes were analyzed using an unconditional
logistic regression model with correction for age using the
SPSS statistical package, version 10 (SPSS Inc., Chicago, IL,
USA). To compare the relative luciferase activity and the
genomic instability analysis, the t  test and the chi-square/
Fisher exact test were used, respectively [43]. Statistical sig-
nificance was considered at a P value of less than or equal to
0.05.
Results
Effect of 5' UTR -26 G>A polymorphism on reporter gene 
expression
To study the effect on expression of BRCA2 5' UTR -26 G>A
polymorphism, HeLa and MCF-7 cells were transiently trans-
fected with reporter gene construct (pGL3Basic) with A or G
at the polymorphic site. Figure 1 (upper panel) shows how the
construct containing the A allele showed significantly higher
expression than the one with the G allele in HeLa (P = 0.013)
as well as MCF-7 (P = 0.003) cell lines. Both HeLa and MCF-
7 cells exposed to various concentrations of ADR for 1 hour
after 24 hours of transfection downregulated the overall
expression as expected, but the trend of A allele expressing
higher than its alternative G allelic form was maintained (Figure
1, lower panel). The increased activation of p53 by ADR treat-
ment was observed in our experiments as well (data not
shown).
Computational assessment of the regulation of BRCA2 
expression by -26 G>A polymorphism
The analysis of the polymorphic region for the presence of a
putative transcription factor binding site by means of the Ali-
Baba 2.1 program [44] revealed that the G>A change creates
a C/EBP alpha (TTTACCAAGC > TTTACCAAAC) binding
site. The presence of an OCT1 binding site almost overlapping
to this region, however, was not affected by the polymorphism.
The analysis of the complete 5' UTR with G or A at the -26
Figure 1
Reporter gene assay with chimeric BRCA2 promoter and 5' untranslated region (UTR) with A or G at the -26 position (upper panel) and the effect  of increasing the dose of adriamycin (0, 1, and 2.5 μM) (lower panel) Reporter gene assay with chimeric BRCA2 promoter and 5' untranslated region (UTR) with A or G at the -26 position (upper panel) and the effect 
of increasing the dose of adriamycin (0, 1, and 2.5 μM) (lower panel).Breast Cancer Research    Vol 9 No 5    Gochhait et al.
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position for RNA secondary structure folding by RNAstructure
program (version 4.3) [45] depicted a 40-base pair (bp) loop
formation in the vicinity of the translation start site and this
structure changed with the change of the G>A base at the
position. Furthermore, RNA secondary structure folding of the
40-bp loop with free energy change (ΔG) calculation, when
compared using two different programs, showed a similar
trend in the results obtained. The base substitution brought a
change in the structure, and the presence of G at the -26 posi-
tion significantly increased ΔG (-9.4 kcal/mole versus -5.1
kcal/mole by RNAstructure V4.3 and -10.46 kcal/mole versus
-7.10 kcal/mole by VRNAAFOLD, The European Molecular
Biology Open Software Suite) [46] when compared with that
of the A allele at the same position (Figure 2).
5' UTR -26 G>A polymorphism in association with breast 
cancer risk
To further assess the relevance of this functional polymor-
phism, a preliminary case-control study was undertaken to
assess the effect of -26 G>A on sporadic breast cancer sus-
ceptibility. Table 1 presents the details of the genotype and
allele frequencies along with the risk calculations. The overall
distribution of genotype frequencies between patients and
controls was found to be significant (P = 0.001). Surprisingly,
the heterozygous genotype provided approximately twice the
protection than the common G/G homozygous state (Pheterozy-
gote advantage model = 0.0005, odds ratio [OR] = 0.5, 95% confi-
dence interval [CI] = 0.4 to 0.8). However, there was no
significant difference in the distribution of the A/A
homozygous genotype in comparison with the G/G
homozygous state (P = 0.677, OR = 1.1, 95% CI = 0.6 to 2.1)
and the allele frequencies (P = 0.092).
Heterozygous genotype in association with genomic 
instability
To test the hypothesis that the BRCA2 heterozygous geno-
type provides protection in comparison with either of the
homozygous genotypes at the -26 position in the 5' UTR,
allelic imbalance for the selected informative markers in chro-
mosomes 16 and 17 was studied along with mutation in the
p53 gene (mutation details provided in Additional File 1) in a
panel of normal and tumor tissues already characterized for
the polymorphism. Interestingly, the tumors with a hetero-
zygous background for the polymorphism showed a
decreased frequency of allelic imbalance for the three inform-
ative markers each on chromosomes 16 and 17 as well as p53
somatic mutations when compared with either of the
homozygous tumors (Figure 3). Further delineation of geno-
type comparisons showed that GG versus GA (P = 0.038, P
= 0.009) was significant compared with AA versus GA (P =
0.771, P = 0.129) for allelic imbalance in chromosomes 16
and 17, respectively. Inversely, AA versus GA (P = 0.076)
showed a nonsignificant trend toward association compared
with GG versus GA (P = 0.613) when p53 somatic mutations
were compared. Incidentally, both the 5' UTR of BRCA2 and
exon 4 of the p53 gene did not show any somatic variation in
tumor tissues of the studied samples.
Status of p53 codon 72 Arg/Pro polymorphism and its 
interaction with BRCA2 -26 polymorphism
The overall genotype frequency distribution at the codon 72
locus between patients and controls was found to be signifi-
cantly different (P  = 0.001). The p53  codon 72 Arg
homozygous genotype (P = 0.0005, OR = 2.3, 95% CI = 1.4
to 3.6) as well as the Arg allele (Pallele model = 0.0002, OR =
1.7, 95% CI = 1.2 to 2.0) were significantly over-represented
in patients (Table 1). Stratified genotypic data to assess the
combined influence of both p53 and BRCA2 polymorphisms
on breast cancer risk revealed that the G/A at the -26 position
of BRCA2 in combination with the Pro allele at the codon 72
locus provided fivefold protection against breast cancer (P =
0.0001, OR = 0.2, 95% CI = 0.1 to 0.4) (Table 2).
Discussion
The failure of mutational inactivation of the BRCA2 gene to
show an association with breast cancer, specifically the spo-
radic form, in two recent reports from India [14,15] indicated
the need to further explore the involvement of BRCA2  in
Figure 2
Effect of -26 G/A polymorphism on the 5' untranslated region second- ary structure of RNA and stability analyzed by the RNAstructure pro- gram (version 4.3) and VRNAAFOLD (The European Molecular Biology  Open Software Suite) Effect of -26 G/A polymorphism on the 5' untranslated region second-
ary structure of RNA and stability analyzed by the RNAstructure pro-
gram (version 4.3) and VRNAAFOLD (The European Molecular Biology 
Open Software Suite). The -26 position with G or A is indicated by 
arrows.Available online http://breast-cancer-research.com/content/9/5/R71
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breast cancer susceptibility, with altered expression as a pos-
sibility. We propose that -26 G>A polymorphism in the 5' UTR
of BRCA2 has a regulatory role and acts as one of the risk fac-
tors, modulating the function of BRCA2  in breast cancer
pathogenesis, further influenced by codon 72 polymorphism in
the p53 gene.
The functional characterization of the common G>A polymor-
phism in the BRCA2 -26 5' UTR by reporter assay revealed
that the A allele led to higher expression than the G allele in
both HeLa and MCF-7 cell lines. This suggests that the poly-
morphism might have a role in the regulation of BRCA2
expression. Upholding the same trend by ADR treatment fur-
ther implied that the -26 polymorphism might regulate BRCA2
expression independent of other factors, specifically to the
repression of the BRCA2 promoter by ADR via p53 activation
[21]. A search for a consensus sequence for the putative tran-
scription factor in the polymorphic site revealed the creation of
a C/EBP alpha transcription binding site by the change from
G>A in the -26 polymorphic position. However, the presence
of an OCT1 binding site almost overlapping to this region, not
affected by the polymorphism, makes the transcriptional con-
trol hypothesis an unlikely one, unless proven by the gel shift
or chromatin immunoprecipitation assays. The analysis of the
5' UTR for the RNA secondary structure by two different pro-
grams showed that the presence of G at -26 stabilized the
loop at the vicinity of the translation start site, which could
decrease the efficiency of the translation and thereby
decrease the expression of BRCA2. This finding of ours is
supported by the classic work of Vega Laso and colleagues
[47] and Kozak [48], who have argued that the extent of a hair-
pin negative effect on eukaryotic mRNA translation in vivo
depends upon its stability and localization within the molecule.
The -26 G>A polymorphism in the 5' UTR of BRCA2 has been
analyzed in some cancer types. In one study, the -26A allele
was reported to show a borderline association with ovarian
cancer, but similar results in breast cancer with BRCA1 muta-
tion carriers were not found [49]. Another study showed a
monotonic increase in the frequency of the heterozygous G/A
genotype from the lowest to highest risk groups of esophageal
squamous cell carcinoma from northern China [50]. Our
observation supports a heterozygote-protective model, which
has been well recognized in infectious diseases [51] and is
Table 1
Genotype and allele frequencies of BRCA2 -26 and p53 codon 72 polymorphisms in sporadic breast cancer patients and normal 
controls
Genotypes Patients Controls Pa Pb Pc OR (95% CI)d
N = 243 N = 333
BRCA2, exon 2, -26G>A
G/G 144 (59.3%) 157 (47.1%) - 1.0 (referent)
G/A 74 (30.5%) 152 (45.6%) 0.0005e 0.5 (0.4–0.8)
A/A 25 (10.3%) 24 (7.2%) 0.002, 0.116 0.001 0.677 1.1 (0.6–2.1)
G 74.50% 70.00% 0.092 1.2 (1.0–1.6)
p53, exon 4, codon 72 Arg>Pro
Pro/Pro 48 (19.8%) 97 (29.1%) - 1.0 (referent)
Pro/Arg 109 (44.9%) 160 (48.0%) 0.119 1.4 (0.9–2.1)
Arg/Arg 86 (35.4%) 76 (22.8%) 0.210, 0.521 0.001 0.0005e 2.3 (1.4–3.6)
Pro 42.20% 53.20% 0.0002e 0.6 (0.5–0.8)
aP value for Hardy-Weinberg equilibrium testing. bP value for 3 × 2 chi-square test of comparison of overall genotype frequencies between breast 
cancer patients and controls. c,dP values and corresponding age-adjusted ORs with 95% CIs for comparison of genotype frequencies between 
breast cancer patients and controls by logistic regression (not adjusted for age in allele frequency comparisons); the referent genotypes were 
considered on the basis of highest proportion of a homozygous genotype at any particular locus in the control group. eP values continue to remain 
significant after applying Bonferroni correction of 2 (2 single-nucleotide polymorphisms tested in a case-control group) to correct for multiple 
comparisons. CI, confidence interval; OR, odds ratio.
Figure 3
Comparison of allelic imbalance in chromosomes 16 and 17 along with  mutation in p53 with -26 G>A polymorphism background Comparison of allelic imbalance in chromosomes 16 and 17 along with 
mutation in p53 with -26 G>A polymorphism background. P values 
given are for overall distribution, G/G versus G/A, and A/A versus G/A.Breast Cancer Research    Vol 9 No 5    Gochhait et al.
Page 6 of 8
(page number not for citation purposes)
consistent with the initial findings of Healey and colleagues
[52] in sporadic breast cancer. An increased genomic instabil-
ity in the homozygotes compared to heterozygotes substanti-
ates the protective nature of the heterozygous genotype. The
differential results of the association study as reported previ-
ously could be due to the outcome of various single-nucleotide
polymorphism (SNP)–SNP and SNP–environment interac-
tions, again modulated by population and disease type. Never-
theless, our observations of the A allele associated with higher
expression and increased genomic instability via inhibition of
p53  transactivation [4,19,20] and of the G allele with low
expression impairing the DNA repair leading to genomic insta-
bility [53-55] apparently explain the risk provided by the
homozygous state of the two alleles A and G to breast cancer.
Our results also showed that either of the homozygous forms
is associated with increased allelic imbalance or p53 muta-
tions, which again is in line with the findings on consequences
of aberrant expression of BRCA2 [4,19,20,53-55]. On the
basis of these observations, it seems apparent that a germline
heterozygosity status at -26 5' UTR may therefore confer a
protective phenotype characterized by intermediate levels of
BRCA2 expression and an optimal balanced DNA damage
response, specifically to double-strand breaks.
To test the SNP–SNP interaction model, functional polymor-
phism at codon 72 of p53  was considered based on the
emerging hypothesis that variants in many genes along related
biological pathways combine to influence breast cancer risk.
The two alleles of the Arg72Pro polymorphism of p53 differ in
their biological activities. The Pro allele is associated with
increased transcription of p53 target genes via greater binding
to transcriptional machinery and thus shows higher rates of G1
arrest than the Arg allele [22]. In contrast, the Pro allele is less
efficient in suppressing transformation (likely due to reduced
apoptotic potential) than the Arg allele [22-24], which could
be due to efficient binding and regulation by iASPP (inhibitory
member of the ASPP family) [25]. A summary of case-control
reports on the association of codon 72 polymorphism with
breast cancer across the globe, including our results, revealed
an inconsistency in association [26-41], again pointing toward
modulations by multiple factors (Additional File 2). Our analy-
sis of the interaction between -26 BRCA2 and codon 72 p53
polymorphism showed that the simultaneous presence of
protective genotypes, Pro/Pro at the p53 codon 72 locus and
G/A at the -26 BRCA2 locus, rendered fivefold protection
against breast cancer and was approximately twice of what
each genotype rendered alone.
Conclusion
Our study shows that 5' UTR -26 polymorphism of BRCA2
might regulate its expression, albeit not at a transcriptional
level, but at a post-transcriptional level affecting the transla-
tional efficiency. It is interesting to presume that the low-pene-
trating SNP can modulate the fine-tuned regulation of the
multifunctional gene BRCA2, leading to the differential form of
genomic instability and rendering risk to the sporadic form of
breast cancer. This also provides an alternative to the involve-
ment of BRCA2 in the sporadic form in which inactivation by
somatic mutagenesis and methylation is known to be rare. The
analysis also puts into perspective the functional implication of
the dimorphic germline status of p53 in the background of 5'
UTR of BRCA2 in sporadic breast cancer development and
calls for more of such studies in humans to understand the epi-
static effect of genetic backgrounds in the promotion and pro-
gression of the cancer.
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Table 2
Interaction between the polymorphisms: p53 codon 72 and BRCA2 -26 in sporadic breast cancer patients and normal controls
Genotypic combination Patients Controls
p53 codon 72 BRCA2 -26 N = 243 N = 333 Pa OR (95% CI)b
Pro/Pro G/G 38 (15.63%) 45 (13.51%) - 1 (referent)
Pro/Pro G/A 7 (2.88%) 46 (13.81%) 0.0002c 0.2 (0.1–0.4)
Pro/Pro A/A 3 (1.23%) 6 (1.80%) 0.476 0.6 (0.1–2.5)
Pro/Arg G/G 59 (24.27%) 78 (23.42%) 0.686 0.9 (0.5–1.5)
Pro/Arg G/A 38 (15.64%) 68 (20.42%) 0.166 0.7 (0.4–1.2)
Pro/Arg A/A 12 (4.94%) 14 (4.20%) 0.983 1.0 (0.4–2.4)
Arg/Arg G/G 47 (19.34%) 34 (10.21%) 0.120 1.6 (0.9–3.0)
Arg/Arg G/A 29 (11.93%) 38 (11.41%) 0.754 0.9 (0.5–1.7)
Arg/Arg A/A 10 (4.11%) 4 (1.20%) 0.087 3.0 (0.9–10.2)
a,bP values and corresponding age-adjusted ORs with 95% CIs for comparison of combination of genotype frequencies between breast cancer 
patients and controls by logistic regression. cP values continue to remain significant after applying Bonferroni correction of 9 (9 combinations 
tested in a case-control group) to correct for multiple comparisons. CI, confidence interval; OR, odds ratio.Available online http://breast-cancer-research.com/content/9/5/R71
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